Noxopham Annual Report 2025

Fair value of financial instruments The fair values of cash and cash equivalents, trade and other receivables and trade and other payables approximate to their carrying amounts largely due to being liquid assets or liabilities that will be settled within 12 months. Note 15. Fair value measurement Fair value hierarchy The following tables detail the consolidated entity’s assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly Level 3: Unobservable inputs for the asset or liability. Level 1 Level 2 Level 3 Total Consolidated - 2025 $ $ $ $ Liabilities Embedded derivatives of convertible note - - (108,000) (108,000) Total liabilities - - (108,000) (108,000) Level 1 Level 2 Level 3 Total Consolidated - 2024 $ $ $ $ Assets Nyrada Inc. ordinary shares 1,969,022 - - 1,969,022 Nyrada Inc. performance shares - - 40,802 40,802 Total assets 1,969,022 - 40,802 2,009,824 There were no transfers between levels during the financial year. Refer to Note 7 in relation to the sale of the Nyrada shares during the reporting period, resulting in a nil balance at 30 June 2025. Reconciliation of the fair values at the beginning and end of the current and previous financial year are set out below: Level 1 Level 2 Level 3 30 June 2025 30 June 2024 30 June 2025 30 June 2024 30 June 2025 30 June 2024 Consolidated - 2025 $ $ $ $ $ $ Opening fair value 1,969,022 934,451 - - 40,802 27,601 Addition of embedded derivative of convertible notes - - - - (640,000) - Disposal of investment (2,434,383) - - - - - Fair value gains 465,361 1,034,571 - - 491,198 13,201 Closing fair vale - 1,969,022 - - (108,000) 40,802 Annual Report 2025 38

RkJQdWJsaXNoZXIy MjE2NDg3